SLC5A2 and diabetes mellitus: The first FDA-approved SGLT2 inhibitor, canagliflozin (marketed as Invokana®, developed by Mitsubishi Tanabe Pharma (Osaka, Japan), was introduced in March 2013, marking a significant advancement in diabetes and cardiovascular care.